TY - JOUR T1 - Cancer immunotherapy and toxic epidermal necrolysis JF - BMJ Supportive & Palliative Care JO - BMJ Support Palliat Care SP - 314 LP - 315 DO - 10.1136/bmjspcare-2019-002135 VL - 10 IS - 3 AU - Liyan Zhang AU - Lin Shen AU - Yuhan Lu AU - Jing Xue Y1 - 2020/09/01 UR - http://spcare.bmj.com/content/10/3/314.abstract N2 - Objectives Immunotherapy has come to play an increasingly important role in cancer treatment. Accordingly, immune-related adverse events (irAEs) have drawn considerable attention. In this case, a young female patient developed immune-related toxic epidermal necrolysis (TEN). The same irAEs have been rarely reported in previous studies. In this study, we describe the treatment and care methods used in this case in detail in order to provide a reference for clinical practice.Methods After being diagnosed with TEN, the patient accepted systemic glucocorticoid therapy, timely care of skin and mucous membranes, nutrition support, antiacid therapy, anti-inflammatory, analgesics and other supportive measures.Results The patient’s skin recovered completely, and no serious adverse outcomes, such as secondary infection or multiple organ failure, occurred during treatment.Conclusion Medical staff should be able to identify the performance of rare irAEs such as TENs and actively explore comprehensive treatments to ensure patient safety and avoid adverse outcomes. ER -